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Autosomal dominant polycystic kidney disease is the most
prevalent, potentially lethal monogenic disorder. It has large
inter- and intra-familial variability explained to a large extent
by its genetic heterogeneity and modifier genes. An
increased understanding of its underlying genetic, molecular,
and cellular mechanisms and a better appreciation of its
progression and systemic manifestations have laid out the
foundation for the development of clinical trials and
potentially effective therapies. The purpose of this review is
to update the core of knowledge in this area with recent
publications that have appeared during 2006–2009.
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SCOPE OF THIS REVIEW
Although there have been numerous reviews of this topic in
recent years, the fast pace of the field of polycystic kidney
disease (PKD) justifies frequent re-evaluations and updates.
The purpose of this review is to update the core of knowledge
in this area with recent publications, which have appeared
during 2006–2009. References are limited to these publica-
tions. The reader is referred to earlier reviews for older
references.1–3
Autosomal dominant PKD (ADPKD) is the most
common of the inherited renal cystic diseases, a group of
disorders characterized by the development of renal cysts and
a variety of extrarenal manifestations. It occurs worldwide
and in all races with a prevalence estimated to be between
1:400 and 1:1000. Age-adjusted male/female sex ratios greater
than unity (1.2–1.3) for the yearly incidence rates of ADPKD-
caused end-stage renal disease (ESRD) in Japan, Europe, and
United States suggest a more progressive disease in men than
in women. Consistent with this, a survival analysis of 1391
parent/offspring pairs showed a significant male gender effect
(hazard ratio 1.424; 95% confidence interval 1.180–1.719) on
age at ESRD (58 and 57 years for female and 54 and 54 years
for male parents and offspring), but no difference between
pairs.4
PKD GENES AND PROTEINS
Autosomal dominant PKD is genetically heterogeneous with
two genes identified, PKD1 (chromosome 16p13.3) and
PKD2 (4q21). The PKD1 and PKD2 proteins, polycystin-1
(PC1, B460 kDa) and polycystin-2 (PC2, B110 kDa) con-
stitute a subfamily (TRPP) of transient receptor potential
(TRP) channels (Figure 1).5 Although PC2 (or TRPP2)
exhibits characteristic structural (six transmembrane
domains) and functional (permeability to cations) features
of a TRP channel, PC1 (or TRPP1) is a distant TRP homolog.
Its final six-transmembrane region is similar to the PC2
transmembrane domains and may have PC2-independent
nonselective cation channel activity.
PC1 (4303 aa) has the structure of a receptor or adhe-
sion molecule and contains a large (3074 aa) extracellular
N-terminal region, 11 transmembrane (1032 aa), and a short
(197 aa) intracellular C-terminal region (Figure 1). It inter-
acts with PC2 through a coiled-coil domain in the C-terminal
portion and with multiple other proteins at different
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extracellular and intracellular sites. The interacting partners
and putative functions of these interactions are listed in
Table 1. PC1 is found in the primary cilia, cytoplasmic
vesicles, plasma membrane at focal adhesions, desmosomes,
adherens junctions, and possibly endoplasmic reticulum
and nuclei.
The extracellular portion of PC1 contains a G-protein-
coupled receptor proteolytic site. Cleavage at this site results
in a C-terminal fragment (150 kDa) and an N-terminal
fragment (400 kDa), which remains tethered.12 Pkd1-null
mice die in utero and exhibit renal and pancreatic cysts as
well as placental, vascular, cardiac and skeletal malforma-
tions, but mice with a mutation expressing non-cleavable
PC1 protein survive to P28 with enlarged cystic kidneys.13
This may mean that newly synthesized PC1 can proceed
through competing ‘cleavage’ (critical in embryonic devel-
opment) and ‘non-cleavage’ (critical for maintenance of
tubular integrity) pathways with different functions in vivo,
or that the non-cleavable Pkd1 mutation is a hypomorphic
mutation with residual function.
Two non-mutually exclusive models have suggested that
the C-terminal tail of PC1 can be cleaved and migrate to the
nucleus. In the first, PC1 normally sequesters the transcrip-
tion factor STAT6 on cilia, thereby preventing its activation.
Interruption of luminal fluid flow (for example, after ureteral
clamping or renal injury) triggers the cleavage of the final
112 amino acids. This p112 fragment interacts with STAT6
and the co-activator P100 and stimulates transcriptional
activity.14 In the second, mechanical stimulation of the
primary cilium normally triggers the cleavage and release of
the entire C-terminal tail (p200). This p200 fragment
contains a nuclear localization motif, binds b-catenin in
the nucleus, and inhibits its ability to activate T-cell factor-
dependent gene transcription, a major effector of the
canonical Wnt signaling pathway.9
PC1 normally forms a complex at the adherens junction
with E-cadherin and a-, b-, and g-catenins. Under conditions
of calcium starvation, PC1 and E-cadherin are sequestered in
cytoplasmic vesicles. Calcium restoration triggers the recruit-
ment of both proteins to reforming cell–cell contacts.10 PC1
has been proposed to regulate the mechanical strength of
adhesion between cells by controlling the formation of
stabilized, actin-associated, adherens junctions.15 PC1/E-
cadherin complexes are disrupted in ADPKD, and E-cadherin
is sequestered internally and replaced at the surface by
N-cadherin.
PC2 (968 aa) contains a short N-terminal cytoplasmic
region with a ciliary targeting motif,16 6 transmembrane
domains, and a short C-terminal portion. An earlier accepted
model of the C-terminal portion included a calcium-binding
motif (EF-hand) and partially overlapping coiled-coil
domain and endoplasmic reticulum retention motif. A recent
molecular modeling and biophysical analysis of the C-
terminal portion predicts a globular EF-hand motif that
undergoes calcium-induced conformational changes, con-
nected by a linker to a previously unidentified, elongated
coiled coil, C-terminal to the position of the coiled-coil
domain in the earlier accepted model (Figure 1). Residues
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Figure 1 | Diagram of the PKD1 protein, polycystin-1 (left) and the PKD2 protein, polycystin-2, and their interaction through coiled-
coil domains in the C-terminal tails (according to the revised molecular model).6 Details of the domains and regions of homology are
shown in the key. Recently, it has been proposed that polycystin-1 may activate transcription directly by cleavage and translocation of the
C-terminus to the nucleus, a process found in other transmembrane proteins. The cleavage site in the GPS region and possible cleavage
sites in the C-terminal tail of polycystin-1 are marked with arrows. TRP, transient receptor potential.
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within the newly identified coiled coil are necessary for
binding to PC2-interacting proteins PC1, TRPC1, and KIF3A
and for PC2-PC2 oligomerization. This domain includes the
most C-terminal pathogenic PKD2-associated truncation
variant (R872X).6 An N-terminal dimerization domain has
also been identified.17 Table 2 lists the proteins known to
interact with PC2 and the functional significance of these
interactions.
The subcellular localization of PC2 has been controversial.
It has been shown to localize predominantly to the
endoplasmic reticulum, but also to the plasma membrane,
primary cilium, centrosome, and mitotic spindles in dividing
cells. Its subcellular transport and localization are controlled
by phosphorylation and multiple interactions with adapter
proteins.31 Interaction with PIGEA-14 (Polycystin-2 inter-
actor, Golgi- and endoplasmic reticulum-associated protein
with a molecular weight of 14 kDa) augments forward
trafficking from the endoplasmic reticulum to the cis-Golgi,
while interaction with PC1 facilitates its translocation to the
plasma membrane. Phosphorylation of PC2 by casein kinase
2 mediates binding to phosphofurin acidic cluster sorting
protein-1 and -2 (PACS-1 and PACS-2), two connector
proteins that mediate retrieval back to the trans-Golgi
network (PACS-1) and the endoplasmic reticulum (PACS-2).
Recently PC1 and PC2, as well as fibrocystin (the protein
mutated in autosomal recessive PKD), have been located in
exosomes.32 These are small vesicles (50–100 nm in diameter)
produced by the multivesicular body sorting pathway.
Membrane proteins are uniquely packaged into intra-
luminal vesicles within the multivesicular body, some of
which are excreted when these multivesicular bodies fuse
with the apical plasma membrane. They are produced by a
variety of cell types and have profound biological effect in
the immune system and in the embryonic node for left/right
(L/R) axis determination. Urine contains a sub-population
of exosomes that contain large amounts of PC1, PC2, and
fibrocystin. In vitro studies showed that these exosomes
preferentially adhere to primary cilia of kidney and biliary
epithelial cells in a rapid and highly specific manner and
may represent a novel ‘urocrine’ signaling system mediated
through a subset of primary cilia.
DISEASE VARIABILITY: GENIC, ALLELIC, AND GENE MODIFIER
EFFECTS
Genic, allelic, and gene modifier effects contribute to the high
phenotypic variability of ADPKD. PKD1- is more severe than
PKD2-associated disease (age at ESRD 54.3 versus 74.0 years
for PKD1 and PKD2, respectively). The greater severity of
Table 1 | Proteins interacting with PC1 and putative functions
Polycystin-1 interacting protein Putative function Referencea
PC2 (TRPP2) A coiled-coil domain within the C terminus of PC1 binds to the C terminus of PC2.
This interaction stabilizes PC2 and affects its trafficking and channel function
b-subunit of casein kinase II
(CK2b)
The PLAT domain of PC1 interacts with CK2b. CK2 phosphorylates and activates
the PC2 channel in a PC1–PC2 complex
Hu et al.7
Polycystin L Functional significance not known Bui-Xuan et al.8
Tuberin Localizes PC1 to lateral membranes of renal epithelial cells
Heterotrimeric G proteins The C terminus of PC1 binds heterotrimeric Gi/Go and c-Jun N-terminal kinase (JNK)
and AP-1
Regulator of G protein signaling 7
(RGS7)
The C terminus of PC1 binds RGS7, a modulator of G-protein-dependent signaling,
and inhibits its degradation
Janus kinase 2 (JAK2) PC1 binds and activates JAK2 in a PC2-dependent manner. This leads to activation
of STAT3 and upregulation of the cyclin-dependent kinase inhibitor p21waf1
Na+/K+ATPase a-subunit The C terminus of PC1 binds the Na+/K+ATPase a-subunit and modulates its activity
Cell–cell adherens junction
components (E-cadherin, a, b,
and g-catenins)
Multiprotein complex that regulates cell–cell contacts and their interactions with
the cell cytoskeleton in epithelial cells
b-catenin The cleaved PC1 C-terminal tail binds b-catenin in the nucleus and inhibits its
ability to activate T-cell factor–dependent gene transcription
Lal et al.9
Annexin A5 Interacts with the LRR domain of PC1 and inhibits the recruitment of E-cadherin to
reforming cell contacts in calcium-starved MDCK cells after calcium restoration
Markoff et al.10
Flotillin-2 Serves to organize the PCs and associated E-cadherin and b-catenin into a signaling
membrane domain
Focal adhesion protein
components (a2b1 integrin, talin,
paxillin, vinculin, a-actinin, focal
adhesion kinase, c-src, p130-cas,
nephrocystin, proline-rich kinase
pyk-2, and tensin)
Multiprotein complex that regulates extracellular matrix interactions with the
plasma membrane and cell cytoskeleton in epithelial cells
Intermediate filament proteins
(Vimentin, cytokeratins K8 and
K18, and desmin)
Structural and signaling functions at cell junctional complexes
Human homolog of Drosophila
Seven in Absentia (Siah-1)
Promotes the degradation of PC1 through ubiquitin–proteasome pathway
Homer-1a/Vesl-1S Synaptic remodeling/plasticity responses of hippocampal neurons Stokely et al.11
aOnly articles published during 2006–2009 are referenced.
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PKD1 is due to the development of more cysts at an early age,
not to faster cyst growth.33 Both PKD1 and PKD2 can be
associated with severe polycystic liver disease (PLD) and
vascular abnormalities. Due to the lesser severity of the
renal involvement, the prevalence of PKD2 associated
disease has likely been underestimated in clinically studies.
Table 2 | Proteins interacting with PC2 and putative functions
Polycystin-2 interacting protein Putative function Referencea
PC1 (TRPP1) A coiled-coil domain within the C terminus of PC1 binds to the C terminus of
PC2. This interaction may stabilize PC1
PC2 Forms oligomers (possibly required to form a functional channel) through
both C-terminal and N-terminal dimerization domains
Celic et al.6, Feng et al.17
PC2 interactor, Golgi- and endoplasmic
reticulum–associated protein (PIGEA-14)
Regulates the intracellular location of PC2 and induces its translocation to the
trans-Golgi network
Phosphofurin acidic cluster sorting
protein (PACS)-1 and PACS-2
Regulates the routing of PC2 between endoplasmic reticulum, Golgi, and plasma
membrane compartments
Family of Rab11-interacting protein 2
(FIP2)
Scaffold protein induced by TNFa that interacts with PC2 and prevents its
translocation to the primary cilium
Li et al.18
Pericentrin Centrosomal protein that interacts with PC2 and is required for assembly of
primary cilia
Collectrin Membrane protein in the primary cilium and vesicles near the basal body of
collecting duct cells involved in intracellular and ciliary movement of vesicles
and membrane proteins. Knockdown in metanephric culture results in cystic
dilatation of ureteric bud branches
Zhang et al.19
Kinesin-2 subunit KIF3A Binds and regulates the activity of PC2 in primary cilia Li et al.20
Kinesin-2 subunit KIF3B Acts as a linker between PC2 and fibrocystin and mediates the regulation
of PC2 channel function by fibrocystin
Wu et al.21
Fibrocystin Fibrocystin interacts with the N terminus of PC2 and prevents PC2
downregulation
Kim et al.22
Epidermal growth factor receptor
(EGFR)
Activation of EGFR releases PC2 from PIP2 inhibition through PLC-g2-induced
activation and PI3K-induced conversion of PIP2 to PIP3
Phospholipase C-g2 (PLC-g2) See above
Mammalian Diaphanous (mDia1) Facilitates the movement of PC2 to a centralized position during cell division
and affects intracellular calcium homeostasis during mitosis
Kidney injury molecule 1 (Kim 1) Member of the T-cell immunoglobulin mucin family that may act as a ciliary
chemosensor modulating the function of PC2
Kuehn et al.23
Inositol 1,4,5-trisphosphate receptor
(IP3R)
PC2 physically interacts with IP3R through its C terminus and modulates its
channel activity
Ryanodine receptor 2 (RyR2) The N terminus of PC2 binds the RyR2. The C terminus of PC2 binds to RyR2
only in its open state, inhibiting its channel activity
Anyatonwu et al.24
Syntaxin 5 Interacts with the N terminus of and inactivates PC2, preventing the leakage
of calcium from endoplasmic reticulum stores
Geng et al.25
Transient receptor potential channel
(TRPC1)
PC2 interacts with TRPC1 through two distinct domains (C terminal coiled-coil
and transmembrane domains), possibly affecting store–operated calcium entry
Transient receptor potential channel
(TRPC4)
PC2 interacts with TRPC4 (and TRPC1) in mesangial cells, possibly forming
store–operated calcium channels
Du et al.26
Transient receptor potential channel
(TRPV4)
Interacts with the C terminus of PC2 and is an essential component of the
ciliary flow sensor in MDCK cells. However, TRPV4 knockout mice do not have
renal cysts
Kottgen et al.27
Pancreatic ER-resident eIF2a kinase
(PERK)
PC2 promotes PERK-mediated phosphorylation of eukaryotic translation
initiation factor eIF2a and negatively controls cell growth
Liang et al.28
Eukaryotic translation initiation factor eIF2a See above Liang et al.28
Helix-loop-helix protein Id2 PC2 binds Id2 in a PC1-dependent manner, preventing its translocation to the
nucleus and suppression of p21waf
CD2-associated protein (CD2AP) Mediates the association of PC2 with multimeric intracellular and membrane
complexes in renal tubular epithelia
Hax-1 Links PC2 to F-actin-binding protein cortactin and actin cytoskeleton
Tropomyosin-1 A component of the actin microfilament network; interacts with the C terminus
of PC2
a1- and a2-actinin Components of cell–cell and cell–matrix contacts, interact with both N- and
C-termini of PC2 and stimulates its channel activity
Troponin-I A component of the actin microfilament network, interacts with the C terminus
of PC2
Homocysteine-induced endoplasmic
reticulum protein (Herp)
Ubiquitin-like protein implicated in regulation of PC2 degradation Liang et al.29
ATPase p97 Component of a protein complex that retro-translocates ubiquitinated
substrates from the endoplasmic reticulum to the cytosol
Liang et al.29
Transcriptional coactivator with
PDZ-binding motif (TAZ)
Interacts with the C terminus of PC2, links PC2 to an SCFb-Trcp E3 ligase
complex, and promotes ubiquitin-dependent PC2 proteolysis. TAZ knockout
mice develop PKD
Tian et al.30
aOnly articles published during 2006–2009 are referenced.
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Population-based studies in communities where disease
ascertainment is likely to be more complete, such as in
Olmsted County and Newfoundland, reveal relative frequen-
cies of PKD2 (36 and 29%, respectively) which are higher
than in clinical studies (10–15%).34,35
PKD1 and PKD2 mutations are highly variable and
usually private. The ADPKD Mutation Database (http://
pkdb.mayo.edu) lists 333 truncating PKD1 mutations
identified in 417 families with a total of 869 variants,
including missense mutations and silent polymorphisms.
Ninety-five PKD2 truncating mutations are listed in 178
families, with a total of 128 different variants.
A recent study screened the 202 probands in the
Consortium for Radiologic Imaging Study of PKD (CRISP)
ADPKD population by denaturing high-performance liquid
chromatography, followed by direct sequencing. Definite trun-
cating mutations and probable (missense, atypical splicing
and small in-frame changes) mutations were identified in
127 (62.9%) and 53 (26.2%) probands, respectively.36 Of these,
153 (85.0%) were in PKD1 and 27 (15.0%) in PKD2. Thirty
percent of mutations were recurrent; hence 70% were unique
to a single family. In a subsequent study, a multiplex ligation-
dependent probe amplification assay detected large deletions
(n¼ 3) or duplications (n¼ 1) in four probands, thus increas-
ing the level of detection to 184 of 202 (91.1%).37 The
molecular basis of disease in approximately 9% of ADPKD
in the CRISP population remained unclear. A similar overall
mutation rate (86%) was observed in a smaller study using a
Transgenomic’s SURVEYOR Nuclease and WAVE nucleic acid
high sensitivity analysis system (Omaha, NE, USA).38
Compared with genic (PKD1 vs PKD2) effects, the
influence of allelic factors (mutation type or location) on
the severity of ADPKD is limited. Patients with mutations in
the 50 region of PKD1 have more severe disease (18.9 vs
39.7% with adequate renal function at 60 years) and are more
likely to have intracranial aneurysms and aneurysm ruptures
than patients with 30 mutations. No clear correlations were
found with mutation type in PKD1 or PKD2 or with
mutation type or position in PKD2. More recently, however,
hypomorphic or incompletely penetrant PKD1 or PKD2
alleles have been described.39 These alleles alone may result in
mild cystic disease; two such alleles cause typical to severe
disease; and in combination with an inactivating allele may
be associated with early-onset disease.
The large intra-familial variability of ADPKD highlights a
role for genetic background in disease presentation. Bilineal
inheritance of a PKD1 and PKD2 mutant allele or of PKD1 or
PKD2 hypomorphic alleles can result in variable degrees of
enhancement to single gene phenotypes. Mosaicism can also
modulate the disease presentation and result in marked intra-
familial variability.37,40 Renal enlargement in utero or in
infancy more typical of autosomal recessive PKD may occur
in a small proportion of cases. Most early-onset cases have
been linked to PKD1, but recently a PKD2 family with
perinatal death in two severely affected infants was
described.41 The high risk of recurrence of ADPKD with
early manifestations in affected families suggests a common
familial modifying background for early and severe disease
expression (for example, mutations or variants in genes
encoding other cystoproteins). The best-documented exam-
ple (apart from hypomorphic PKD1 alleles) is the contiguous
deletion of the adjacent PKD1 and TSC2, characterized by
childhood PKD with additional clinical signs of tuberous
sclerosis complex.
Other modifying loci likely account for more common
and subtle intra-familial variability. Studies of candidate loci,
selected because of presumed relevance to the pathogenesis of
ADPKD or association with prognosis in other renal diseases,
have been mostly disappointing. Most studies have not found
an association between the I/D polymorphism in the
angiotensin-I-converting enzyme (ACE) and early ESRD.42,43
Studies of other components of the renin–angiotensin system
have been negative. The Glu298Asp polymorphism of
endothelial nitric oxide synthase has been associated with
earlier ESRD,44 but this has not been a consistent finding. A
functional length polymorphism in the promoter region of
the human heme oxygenase-1 (HO-1) gene that results in
higher HO-1 expression and enzyme activity had no effect on
age at ESRD, despite the protective role of HO-1 in a variety
of experimental models of renal injury and its upregulation
in polycystic kidneys.45 Functional polymorphisms of tumor
growth factor-b1 (TGF-b1), bradykinin receptors B1 and B2,
epidermal growth factor receptor (EGFR), and endothelin
ET-A receptor genes and of the regulatory region of the
VEGF gene did not have an effect on disease progression.46–48
ADPKD patients who are TT homozygotes for the –414 T/C
polymorphism in the promoter region of the a-8 integrin
chain gene (ITGA8) were reported to have an earlier onset of
ESRD than those with a C allele (47 vs 51 years of age).49
Despite these mostly negative results, identification of
quantitative trait loci influencing the severity of PKD remains
important for understanding the pathogenesis and providing
insights into potential therapies. High-density single-nucleo-
tide polymorphism arrays allow the mapping of quantitative
trait loci in large, clinically and genetically well-characterized
populations using a genome-wide association study. The feasi-
bility of this approach has been illustrated by the identification
of the first putative modifier of renal disease severity (mapping
to chromosome 4) in PKD as the kinesin gene (Kif12) in the
cpk mouse. Interestingly, Kif12 transcription is regulated by
hepatocyte nuclear factor-1b (HNF-1b) and mutations in
HNF-1b cause an inherited syndrome characterized by renal
cystic disease or dysplasia and diabetes mellitus.50
GENETIC MECHANISMS
Evidence from animal models of ADPKD and analysis of
cystic epithelia have shown that renal cysts may develop from
loss of functional polycystin with somatic inactivation of the
normal allele consistent with a two hit mechanism. However,
dosage reduction of the protein in two Pkd1 animal models
with hypomorphic alleles that generate o20% of the
normally spliced product indicates that cysts can develop
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even if the protein is not completely lost.51 Furthermore,
Pkd1 transgenic mice overexpressing the Pkd1 transgene in
the kidneys 2- to 15-fold over Pkd1 endogenous levels
develop renal cystic disease resembling human ADPKD.52
Transgenic mice overexpressing Pkd2 develop B-Raf and ERK
activation, increased rates of proliferation and apoptosis, and
renal cysts detectable at 6 months and progressive with age.53
Transgenic mice overexpressing human PKD2 to the levels of
30–100% of the expression of the endogenous mouse Pkd2
show mild tubular dilatation, microcysts (in a minority of
animals at 8 months of age), and tubular cell vacuolization,
disorganization of the renal cortex, and abnormal expression
of extracellular matrix (ECM) in older animals.54 Transgenic
rats expressing a truncated human PKD2 cDNA lacking
almost the entire C terminus to levels 7- to 15-fold higher
than those of endogenous Pkd2 mRNA develop PKD and
retinal degeneration.55 These animal models suggest that
multiple genetic mechanisms that result in an imbalance in
the expression of polycystins can affect their function and
lead to the development of PKD.
Centrosomal amplification occurs in kidneys from condi-
tional Pkd1 knockout mice, Pkd2-knockout mice, PKD2-
overexpressing mice, and from patients with ADPKD.56,57
Knockdown of Pkd1 expression using small interfering RNA
induces centrosomal amplification, multipolar spindle for-
mation, polyploidism, and mitotic catastrophe, followed by a
convergence of the cell population toward a stable ploidy in
which centrosomal amplification is significantly decreased,
but cytological abnormalities and aneuploidy remain com-
mon.56 The link between derailed levels of polycystin
expression, centrosome integrity and genomic stability may
reconcile the haploinsufficiency, gene dose effect, and two-hit
hypotheses of cystogenesis. This model is consistent with the
evidence of cyst formation from a relative low number of
tubules, the presence of apoptotic cells in both tubular and
cystic cells in ADPKD kidneys, the clonality of cystic
epithelia, and the high frequency of chromosomal anomalies
and genetic aberrations in cystic cells from patients with
ADPKD. It may also account for the low rate of development
of renal cell carcinoma in ADPKD, despite the frequency of
hyperplastic polyps and microscopic adenomas, as recent
evidence indicates that high levels of genomic instability may
inhibit tumorigenesis.58,59
Conditional knockouts of ciliogenic genes (Tg737 and
Kif3a) or of Pkd1 at various time points have shown that the
timing of ciliary loss or Pkd1 inactivation determines the
rate of development of cystic disease.60–63 Kidney develop-
ment is not yet completed in newborn mice. Inactivation of
Pkd1 before postnatal day 13 results in rapidly progressive
cystic disease, whereas later inactivation causes much slower
cyst development.61 The kidney-specific inactivation of Kif3a
in newborn mice leads to rapid cyst development in the loops
of Henle, whereas inactivation at postnatal day 10 or later
does not, despite comparable loss of primary cilia.60 Cysts
also develop rapidly in the corticomedullary region (pars
recta and thick ascending limbs of Henle) of adult mouse
kidneys subjected to renal ischemic/reperfusion injury to
stimulate cell proliferation (but not in contralateral control
kidneys), when Kif3a is conditionally inactivated.64 Analysis
of pre-cystic tubules show that the loss of cilia results in
aberrant planar cell polarity manifested by abnormalities in
the orientation of cell division. The age-dependence,
location, and induction of the cysts by ischemia-reperfusion
injury suggest that cyst formation is associated with increased
rates of cell proliferation. However, inactivation of Pkd1 at
postnatal day 14 or of Kif3a at postnatal dates 10–14, when
the rates of cell proliferation are higher than in the adult, but
lower than in younger animals, fails to induce cyst formation.
This suggests that a certain threshold of cell proliferation
must be exceeded or that increased cell proliferation is only
one of the factors responsible for the higher rate of cyst
formation in newborn compared with older mice. Another
factor could be the transcriptional programming of kidney
cells, which is markedly different in the postnatal period
compared with the adult.61,65 In summary, these observations
in conditional knockouts indicate that PKD1 and cilia are
required to maintain the renal tubular structure in adult
kidneys, that cyst initiation can occur throughout the lifetime
of an individual, and that cyst development occurs much
more rapidly when PKD1 is inactivated or cilia are lost in
developing than in mature kidneys. Although they provide
important insights, it is important to point out that massive
and complete inactivation of PKD1 at a particular time point
is not likely how the development of cystic disease starts in
ADPKD and that consequently these are imperfect models
for this disease.
PATHOGENESIS
The polycystins are essential to maintain the differentiated
phenotype of the tubular epithelium. Reduction in one of
these proteins below a critical threshold results in a
phenotypic switch characterized by inability to maintain
planar polarity, increased rates of proliferation and apoptosis,
expression of a secretory phenotype, and remodeling of the
ECM. The molecular mechanisms responsible for this
phenotypic switch are not known, but hypotheses abound.
Treatment strategies based on them may help to establish
their validity. Given the proposed participation of the
polycystins in numerous signaling pathways at multiple
subcellular locations, they are likely to be complex.
Centrosomal dysfunction or amplification, activation of
canonical b-catenin-dependent Wnt signaling, and inhibition
of non-canonical b-catenin-independent Wnt signaling (that
is, activation of c-jun N-terminal kinase, JNK, and transient
changes in cytosolic calcium concentrations) may be respon-
sible for the loss of planar cell polarity, which may be key to
the transformation of a tubular into a cystic structure.
A recent study has shown that secreted Frizzled-related
protein 4 (sFRP4) is upregulated in human ADPKD9,66 and
in four different animal models of PKD (Pkd2/, Invs/,
and pcy mice, and Han:SPRD rat) and is detected in the urine
of patients and animals with PKD, but not in the urine of
154 Kidney International (2009) 76, 149–168
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healthy individuals.66 sFRP4 is a member of a family of
secreted molecules that antagonize Wnt signaling. Interest-
ingly, it inhibits only select members of the canonical Wnt
signaling pathway, possibly explaining why b-catenin can
accumulate in PKD in the presence of elevated sFRP4
concentrations. The sFRP4 promoter contains lymphoid
enhancer-binding factor-1-, STAT3-, and cAMP-responsive
element-binding sites. Because the lymphoid enhancer-
binding factor-1-binding site can be stimulated by active
b-catenin, it is conceivable that canonical Wnt signaling, not
blocked by sFRP4, stimulates sFRP4 production. Cyst fluid
and vasopressin stimulate, while a vasopressin V2 receptor
antagonist has an a marked inhibitory effect on the
expression of sFRP4 in inner medullary collecting duct
cells in vitro and in kidneys of pcy mice in vivo. Microinjec-
tion of sFRP4 into zebrafish embryos induces pronephric
cyst formation, heterotaxia, and abnormal body curvature.
Therefore, increased sFRP4 expression in PKD is more likely
to be disease-promoting than an adaptive mechanism to
protect the kidney from the detrimental effects of uncon-
trolled canonical Wnt signaling.
Many pathways that couple cell surface receptors (GPCRs,
TKRs, integrins, and so on) and epithelial cell proliferation
are activated in PKD. These include mitogen-activated
protein kinase/extracellular regulated kinase and mammalian
target of rapamycin (mTOR). In addition, several studies
have implicated the polycystins directly in the regulation of
the cell cycle. PC1 was reported to activate JAK2/STAT-1
signaling, upregulate p21waf (a cell cycle inhibitor), inhibit
cyclin-dependent kinase 2 (Cdk2), and induce cell cycle arrest
in G0/G1 in a PC2-dependent manner. PC2 was reported to
bind Id2, a helix-loop-helix protein in a PC1-dependent
manner, and prevent its translocation to the nucleus and
suppression of p21waf, thus preventing Cdk2 activation and
cell cycle progression. Consistent with these studies, p21waf
levels have been found to be reduced in human and animal
PKD tissues as well as in affected cell lines.67 However, a
recent study has found a different Cdk inhibitor (p57KIP2) to
be downregulated, along with upregulation of Cdk2, in
primary tubular epithelial cells isolated from a PKD2
transgenic rat.68
PC1 and PC2 may also suppress cell growth through the
control of the protein synthesis initiation machinery. PC1
interacts with tuberin to suppress mTOR and activation of
the downstream translation initiation factor eIF4E. PC2
interacts with pancreatic eIF2a kinase (PERK) in the
endoplasmic reticulum and enhances PERK-dependent
phosphorylation of the translation initiation factor eIF2a.28
Numerous studies have shown that increased tubular cell
proliferation is accompanied by increased apoptosis in
PKD.69 The induction of resistance to apoptosis by PC1 has
been attributed to GiCPR activation of phosphatidylinositol
3-kinase (PI3K) and Akt. However, the role of PI3K and Akt
in PKD remain uncertain, as PI3K and Akt activation, along
with increased apoptosis, have been shown in animal models
of PKD.70 Interestingly, overexpression of PKD1 has been
shown to induce G0/G1 phase arrest in cell cycle progression
and an increase in the rate of apoptosis in cancer cell lines.71
Although PC1 knockdown in MDCK cells is associated with
increased rates of proliferation and apoptosis, it is also
accompanied by increased adhesion to collagen type I and
resistance to anoikis (apoptosis triggered by loss of cell
anchorage) probably due to increased expression of integrin-
a2b1.72
Beyond the loop of Henle, tubular epithelial cells have the
capacity to secrete as well as to reabsorb solutes and fluid.
Normally, absorptive flux overshadows secretory flux.
Sodium chloride reabsorption in cortical collecting duct
principal cells, arguably the main origin of the cysts in
ADPKD, is driven by low intracellular sodium concentration
generated by basolateral Na-K-ATPase. Sodium chloride
enters the luminal membrane through the epithelial sodium
and chloride channels. Apical recycling of potassium occurs
through renal outer medullary K (ROMK) channels. Water
enters the cells across the luminal membrane through
vasopressin-sensitive aquaporin-2 channels. Cystic epithelial
cells are markedly different from normal cortical collecting
duct principal cells. Chloride enters across basolateral
NaK2Cl cotransporters, driven by the sodium gradient
generated by basolateral Na-K-ATPase, and exits across
apical protein kinase A (PKA)-stimulated cystic fibrosis
transmembrane conductance regulator (CFTR). Basolateral
recycling of potassium may occur through KCa3.1 (see
below).73,74 Active accumulation of chloride within the cyst
lumen drives sodium and water secretion down transepithe-
lial potential and osmotic gradients. This model for cyst fluid
secretion requires a paracellular pathway sealed by tight
junctions impermeable to chloride. The basic biochemical
infrastructure of the tight junction remains intact even in
late-stage cysts.75 Tight junctions are composed of interacting
proteins, including scaffolding proteins such as ZO-1 and
transmembrane proteins such as occludin and members of
the claudin family. Most of the claudin isoforms expressed in
ADPKD cysts are of distal nephron and collecting duct
origin. Claudin-2, normally expressed in proximal tubules, is
absent from the cysts.
Human and animal models of PKD show an abnormal
expression of matrix-degrading enzymes and inhibitors of
metalloproteinases, necessary for the remodeling of basement
membranes and the surrounding ECM. Cyst-lining epithelia
produce large amounts of structural (collagen I and III,
laminin) and soluble ECM-associated proteins (TGF-b, big-
H3, periostin), which accumulate around the cysts. Some
ECM components (laminin, periostin) actively contribute to
epithelial cell proliferation and cyst growth.
Periostin is a novel autocrine mitogen expressed at high
levels by cyst-derived epithelial cells. It is secreted across
apical and basolateral cell membranes and found in the ECM
adjacent to the cysts and within cyst fluid, but not in normal
kidneys.76 Periostin binds aV-integrins (aVb3- and aVb5-
integrins), that is highly expressed in ADPKD cells, and
activates integrin-linked kinase (ILK). ILK inhibits GSK-3b,
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stabilizes b-catenin, increases nuclear b-catenin levels, and
activates T-cell factor/lymphoid enhancer-binding factor, a
transcription factor involved in cell proliferation. ILK also
activates Akt and lowers the expression of p27Kip1 a cell cycle
kinase inhibitor. The effect of periostin on cell proliferation is
inhibited by aV-integrin-blocking antibodies.
Laminin-5 (a3, b3, g2) is strongly expressed by ADPKD
cells and in the pericystic ECM of ADPKD kidneys, whereas
no laminin-5 expression can be detected in adult control
kidneys.77 ADPKD cells in a three-dimensional gel culture
produce and secrete laminin-5 that is incorporated into
pericystic ECM. Addition of purified laminin-5 stimulates
cell proliferation and cyst formation, whereas blocking
antibodies against laminin-5 inhibit cell proliferation and
cyst formation. Furthermore, a hypomorphic mutation of
laminin-a5, a major tubular basement membrane compo-
nent, results in aberrant accumulation of laminin-5 and
cystic disease in mice.78
DISREGULATION OF INTRACELLULAR CALCIUM AND
cAMP SIGNALING IN PKD
Increasing experimental evidence suggest that the polycystins
are localized in specialized structures that sense the extra-
cellular environment, such as primary cilia, focal adhesions
and adherens complexes, that their function is important for
the regulation of intracellular calcium homeostasis, and that
alterations in intracellular calcium and cAMP signaling play a
central role in the pathogenesis of PKD.
The location of the polycystins that recently has received
the most attention is the primary cilium. In tubular epithelial
cells, the cilium projects into the lumen and is thought to
have a sensory role. The PC1–PC2 complex acts as a sensor
on cilia that translates mechanical or chemical stimulation
into calcium influx through PC2 channels. This in turn
induces calcium release from intracellular stores. PC2
interacts with other TRP channels (TRPC1 and TRPV4),
which may be the components of the mechanosensory
apparatus in primary cilia. ADPKD cyst cells lack flow-
sensitive calcium signaling and show reduced endoplasmic
reticulum calcium stores, store-depletion-operated entry
and, under certain conditions, intracellular calcium
concentrations.
Although PC2 is found mainly in the endoplasmic
reticulum and to a lesser extent in the plasma membrane,
PC1 is found mainly in the plasma membrane and possibly in
the endoplasmic reticulum. Although it seems certain that
PC2 and probably PC1 play an important role in the
regulation of the endoplasmic reticulum calcium stores and
intracellular calcium homeostasis, the precise mechanisms by
which this regulation operates remain uncertain. Calcium
release from intracellular stores decreases gradually with
overexpression, haploinsufficiency, or absence of PC2. In
cardiac myocytes, the N terminus of PC2 binds to RyR2,
whereas the C terminus interacts with the RyR2 in its open
state inhibiting its channel activity.24 Inadequate RyR2
inhibition in cardiac myocytes lacking PC2 results in a
higher frequency of spontaneous oscillations, reduced
sarcoplasmic reticulum calcium stores due to calcium leak,
and reduced calcium transient amplitude compared with
wild-type cells. PC2 interacts with Syntaxin 5 (a member of a
family of proteins, which function in vesicle targeting and
fusion and regulation of the channel activity), inhibits its
channel activity, and prevents leaking of calcium from the
endoplasmic reticulum.25 Overexpression in LLC-PK1 cells of
a truncated PC2 protein that causes PKD and retinal
degeneration in transgenic rats is associated with reduced
endoplasmic reticulum calcium stores. As in the case of
cardiac myocytes lacking PC2, downregulation of PC1
expression and cystic cell lines from PKD1 patients are
associated with a higher frequency of calcium oscillations, in
this case due to increased activity of non-capacitative calcium
entry.79 Heterologous expression of PC1 in MDCK cells also
inhibits the leakage of calcium across the endoplasmic
reticulum membrane.80 ADPKD cyst cells exhibit reduced
endoplasmic reticulum calcium stores, store-depletion-oper-
ated entry and, under certain conditions, intracellular
calcium concentrations.81 Although most of these observa-
tions point to reduced intracellular calcium stores as a
common feature in PKD, another study reported that
overexpression of PC2 in HEK cells increases calcium leakage
and reduces the amount of releasable calcium upon
stimulation with IP3 in the endoplasmic reticulum, whereas
knockdown of PC2 in MDCK cells has the opposite effect
and increases the susceptibility to apoptosis.82
Increased levels of cAMP and expression of cAMP-
dependent genes (such as AQP2 in the kidney) are a common
finding in the kidneys of cpk, jck, pcy, KspCre;
HNF1bflox/floxPkd2/ws25 and gGT.Cre:Pkd1flox/flox mice and
PCK rats,83–85 liver of PCK rats,86 vascular smooth muscle of
Pkd2þ / mice, and choroid plexus of TG737orpk mice.87 In a
recent study, renal cAMP levels and AQP2 expression were
found to be similar in mice with a specific knockout of Pkd1
in collecting duct principal cells compared with controls;
however, the renal cAMP levels in the control animals were
very high compared with earlier studies.88 In view of the role
of PC1 and PC2 in the regulation of intracellular calcium
homeostasis and the importance of calcium in the regulation
of cAMP metabolism by stimulation of calcium inhibitable
adenylyl cyclase 6 and/or inhibition of calcium-dependent
phosphodiesterase 1, it has been suggested that alterations in
intracellular calcium homeostasis account for the accumula-
tion of cAMP. Cyclic AMP in turn contributes to the
development and progression of PKD by stimulating CFTR-
driven chloride and fluid secretion and cell proliferation.
While under normal conditions cAMP inhibits mitogen-
activated protein kinase signaling and cell proliferation, in
PKD or in conditions of calcium deprivation it stimulates cell
proliferation in an Src-, Ras-, and B-raf-dependent manner.
Cell proliferation may be further enhanced by stimulation of
epidermal growth factor (EGF)-like factors present in cyst
fluid, increased insulin-like growth factor-1 in cystic tissues,
and by activation of mTOR, likely due to a disrupted tuberin-
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polycystin-1 interaction or to ERK- or Akt-dependent
phosphorylation of tuberin that prevents its association with
hamartin and inhibits its GTPase activating function for
Rheb.
The abnormal proliferative response to cAMP is directly
linked to the alterations in [Ca2þ ]i, as it can be reproduced
in wild-type cells by lowering [Ca2þ ]i. Conversely, Ca
2þ
ionophores or channel activators can rescue the abnormal
response of cyst-derived cells.89 Upregulation of the vaso-
pressin V2 receptor and high circulating vasopressin levels
may contribute to the increased cAMP levels. A bioactive
lipid with the same biochemical and biological properties as
forskolin, a widely known, potent adenylyl cyclase agonist,
has been isolated and identified within the cyst fluid. It is
conceivable that forskolin is synthesized by mural cyst
epithelial cells, although an exogenous source cannot be
ruled out.90
DIAGNOSIS
The diagnosis of ADPKD usually relies on imaging testing.
Counseling should be done before testing. The risk for
discrimination in terms of insurability and employment has
been reduced, but not eliminated, by the passage into law of
the Genetic Information Nondiscrimination Act (GINA) on
21 May 2008 (refs 91,92). GINA prohibits insurers from
canceling, denying, refusing to renew, or changing the terms
or premiums of coverage based on genetic information. It
also prohibits employers from making hiring, firing, promo-
tion, and other employment-related decisions based on
genetic factors. Genetic information is defined as information
about an individual’s genetic tests, genetic tests of family
members, or occurrence of a disease in family members of
the individual. GINA, however, applies only to individuals
who are asymptomatic, does not prohibit underwriting based
on information about current health status, and does not
apply to life insurance, disability insurance, or long-term care
insurance.
Renal ultrasound is commonly used because of cost and
safety. Revised criteria have been proposed to improve the
diagnostic performance of sonography in ADPKD (Table 3):
The presence of at least three (unilateral or bilateral) renal
cysts and of two cysts in each kidney are sufficient for
diagnosis of at-risk individuals aged 15–39 years and 40–59
years, respectively.93 For at-risk individuals aged X60 years,
four or more cysts in each kidney are required. Requirement
of three or more cysts (unilateral or bilateral) has a positive
predictive value of 100% in the younger age group and
minimizes false-positive diagnoses, as 2.1 and 0.7% of the
genetically unaffected individuals younger than 30 years have
one and two renal cysts, respectively. In the 30–39 years old,
both the original (2 cysts in each kidney) and the revised (43
cysts, unilateral or bilateral) criteria have a positive predictive
value of 100%.
Although the specificity and positive predictive value of
the sonographic criteria is very high, their sensitivity and
negative predictive value when applied to PKD2 in the 15–29
(69.5 and 78%, respectively), 30–39 (94.9 and 95.4%, respec-
tively), and 40–59 (88.8 and 92.3%, respectively) years old
groups are low. This is a problem in the evaluation of potential
kidney donors, where exclusion of the diagnosis is impor-
tant.93 Because of this, Pei et al.93 proposed that different
criteria are used to exclude a diagnosis of ADPKD in an
individual at risk from a family with an unknown genotype.
They found that an ultrasound scan finding of normal kidneys
or one renal cyst in an individual aged 40 years or older has a
negative predictive value of 100%. The absence of any renal
cyst provides almost certainty for disease exclusion in at-risk
individuals aged 30–39 years with a false-negative rate of 0.7%.
The utility of ultrasonography for disease exclusion is limited
in an at-risk individual who is younger than 30 years and has a
negative or indeterminate scan.
In latter scenario, a negative magnetic resonance imaging
(MRI) or computed tomography (CT) scan may provide
further assurance that he/she is not affected. As part of the
donor evaluation, potential candidates in most transplant
centers undergo contrast enhanced, three-dimensional CT, or
MR angiographic imaging. The resolution of these techniques
is much higher than that of ultrasound. Three millimeter
rather than 10 mm cysts are readily detected. These high
resolution imaging modalities show a prevalence of cysts in
the general population, which is at least four times higher than
observed by ultrasound. Therefore, the negative predictive
value of a negative high resolution CT or MR, although not
quantifiable because the proper study has not been performed,
is undoubtly much higher than that of ultrasound.
Recently Huang et al.94 proposed an algorithm that
incorporates the use of DNA testing for the evaluation of
donors at 50% risk of ADPKD inheritance. This algorithm
proposes that potential kidney donors who are less than 30
years old with o3 renal cysts or 30–39 years old with 1–2
renal cysts or 40–59 years old with multiple cysts in one
kidney and 0–1 cyst in the other should have genetic testing.
The algorithm does not differentiate between cysts detected
by ultrasound, CT, or MRI. Given the high prevalence of
Table 3 | Sonographic criteria for the diagnosis of ADPKD93
Age
(years) Criteria PPV NPV
Original Ravine’s PKD1 diagnostic criteria
15–29 X2 cysts, unilateral or bilateral 99.2 87.7
30–39 X2 cysts in each kidney 100 87.5
40–59 X2 cysts in each kidney 100 94.8
X60 X4 cysts in each kidney 100 100
Revised unified diagnostic criteria
15–29 X3 cysts, unilateral or bilateral 100 85.5
30–39 X3 cysts, unilateral or bilateral 100 96.4
40–59 X2 cysts in each kidney 100 94.8
X60 X4 cysts in each kidney 100 100
Revised criteria for exclusion of diagnosis
15–29 X1 cyst 96.6 90.8
30–39 X1 cyst 94.0 98.3
40–59 X2 cysts 96.7 100
X60 X4 cysts in each kidney 100 100
Kidney International (2009) 76, 149–168 157
VE Torres and PC Harris: Autosomal dominant PKD r e v i e w
renal cysts detectable by CT or MR in the general population
(for example, 16–20, 21–25, and 31–55% of 18–29, 30–44, and
45–59 years old women and men, respectively, have at least
two renal cysts detectable by MR), the application of this
algorithm would require genetic testing in nearly one-half of
potential living related kidney donors for ADPKD. The
algorithm does not take into account either the information
that may be available on the ADPKD phenotype of the
family. The presence of one affected family member who
developed ESRD by the age of 60 years is highly predictive of
PKD1 (PPV 100%, sensitivity 75%). By contrast, the presence
of one affected family member who remained renal sufficient
or developed ESRD after the age of 70 years is highly
predictive of PKD2 (PPV 95%, sensitivity 75%).95
There are limitations to genetic testing, either by linkage
or mutation analysis.96 Linkage analysis requires accurate
diagnosis, availability and willingness of sufficient affected
family members to be tested and is feasible in fewer than 50%
of families. De novo mutation can also complicate inter-
pretation of results. Molecular testing by direct DNA
sequencing is now possible with likely mutations identified
in B90% of patients.36,97 However, as most mutations are
unique and up to one-third of PKD1 changes are missense,
the pathogenicity of some changes is difficult to prove.36,97
RENAL MANIFESTATIONS
Most manifestations are directly related to the development
and enlargement of renal cysts. A study of 241 patients with
an estimated glomerular filtration rate (GFR) X60 ml/min
followed prospectively with yearly MR examinations by
CRISP has provided invaluable information to understand
how the cysts develop and grow.98 Total kidney volume and
cyst volumes increased exponentially. At baseline, total
kidney volume was 1060±642 ml and the mean increase
over 3 years was 204 ml (5.27%) per year. The rates of change
of total kidney and total cyst volumes, and of the right and
left kidney volumes, were strongly correlated. Baseline total
kidney volume predicted the subsequent rate of increase in
renal volume and was associated with declining GFR in
patients with baseline total kidney volume above 1500 ml.
These results have been confirmed by recent European study
of 100 ADPKD patients with an estimated GFR X70 ml/min
who underwent standardized MR examinations with un-
enhanced sequences 6 months apart. These patients had a
baseline total kidney volume of 1003±568 ml and a
calculated annual growth rate of 5.36%.99
Another study used contrast enhanced CT to monitor
volume changes in 13 patients with more advanced ADPKD
(serum creatinine 1.2–3.0 mg per 100 ml) imaged twice 6
months apart.100 The volumes of kidneys, cysts, fully
enhanced parenchyma, and faintly contrast-enhanced par-
enchyma (referred to as intermediate) were estimated. The
intermediate volume was considered to be renal parenchyma
undergoing tubular atrophy and fibrosis. The ratio of
intermediate over parenchyma volume strongly correlated
with GFR (r 0.81, Po0.001). In addition, there were
significant correlations between percentage changes in
intermediate volume (absolute or relative to parenchyma)
and GFR changes during the observation period (r 0.70 and
0.75, Po0.01), thus supporting a significant relationship
between renal structural and functional changes in ADPKD.
A study in Newfoundland identified all patients with
ADPKD attending nephrology/urology clinics in 1981.35 The
members of 18 families who were at 50% risk for inheriting
ADPKD (136 with PKD1 and 60 with PKD2) were followed
prospectively for 22 years. Median age at initiation of
treatment for hypertension, stage 3 CKD, ESRD, and death
were 46, 50, 53, and 67 years for PKD1, respectively. Median
age to hypertension treatment, stage 3 CKD, and death
were 51, 66, and 71 years, respectively, whereas ESRD was
infrequent, for PKD2. Causes of death were similar, except
for uremia, which was more common in PKD1.
Hypertension is the most common manifestation of
ADPKD and a major contributor to renal disease progression
and cardiovascular morbidity and mortality. Ambulatory
blood pressure monitoring of children or young adults
without diagnosed hypertension often reveals elevated blood
pressures, attenuated nocturnal blood pressure dipping, and
exaggerated blood pressure response during exercise. A recent
study stratified 65 children by blood pressure into three
cohorts: hypertensive (X95th percentile), borderline hyper-
tensive (75–95th percentile), and normotensive (p75th
percentile).101 Both the hypertensive and borderline hyper-
tensive children had significantly higher left ventricular
mass indices than normotensive children. Among normo-
tensive children, indices were significantly higher in those
within the upper quartile of the normal blood pressure.
These observations suggest that target organ damage
develops early in ADPKD and that antihypertensive treat-
ment may be indicated in children with ADPKD and
borderline hypertension.
Several factors contribute to the development of hyperten-
sion in ADPKD. Activation of the intrarenal renin–angio-
tensin system likely plays an important role, whereas there is
controversy on whether the circulating renin–angiotensin
system is inappropriately activated.102 Expression of PC1 and
PC2 in vascular smooth muscle and endothelium, along with
enhanced vascular smooth muscle contractility103 and
impaired endothelial dependent vasorelaxation, suggest that
disruption of polycystin function in the vasculature are
directly involved. PC1 in the primary cilia plays a role in the
translation of physiological changes in fluid shear stress into
cytosolic calcium and nitric oxide signals.104 Other factors
include increased sympathetic nerve activity and plasma
endothelin-1 levels and insulin resistance.
Endothelial vasodilatation and constitutive nitric oxide
synthase activity are reduced in subcutaneous resistance
vessels from patients with ADPKD and normal GFR. Flow-
induced vasodilation of the brachial artery has been found to
be inconsistently impaired,105,106 whereas pulse wave reflec-
tion was amplified suggesting a predominant involvement of
small resistance vessels.107 Reduced coronary flow velocity
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reserve and increased carotid intima-media thickness in
normotensive patients with normal GFR suggest that
atherosclerosis starts early in the course of ADPKD.108
Reduced nitric oxide endothelium-dependent vasorelaxa-
tion in ADPKD may be due to increased plasma levels of
asymmetric dimethylarginine (ADMA).109 Increased oxida-
tive stress in the kidneys, reflected by increased plasma and
urine levels of 13-hydroxyoctadecadienoic acid, may result in
the oxidation of a cysteine residue in the active site of NG,
NG-dimethylarginine dimethylaminohydrolase (DDAH, an
enzyme that metabolizes ADMA in the renal tubules),
reduced renal clearance and increased circulating levels of
ADMA, and inhibition of constitutive nitric oxide synthase.
Even modest increases in plasma ADMA levels have been
associated with impaired endothelial function. Systemic
infusion of non-pressor doses of ADMA into healthy
human individuals impairs vasodilator responses to acetyl-
choline, increases vascular resistance, and decreases renal
blood flow.
In most patients, renal function is maintained within the
normal range, despite relentless growth of cysts, until the
fourth to sixth decade of life. By the time renal function starts
declining, the kidneys usually are markedly enlarged and
distorted with little recognizable parenchyma on imaging
studies. At this stage, the average rate of GFR decline is
approximately 4.4–5.9 ml/min/year. Several mechanisms
account for renal function decline. CRISP has confirmed
earlier studies suggesting a strong relationship with
renal enlargement and shown that kidney and cyst volumes
are the strongest predictors of renal functional decline.98
CRISP also found that renal blood flow (or vascular
resistance) is an independent predictor.110 This points to
the importance of vascular remodeling in the progression of
the disease and may account for cases where the decline of
renal function seems to be out of proportion to the severity
of the cystic disease. Other factors such as heavy use of
analgesics may contribute to CKD progression in some
patients.
Pain, often associated to cyst hemorrhage, infection or
stones, is the most frequent symptom reported by adult
patients. 18-F-fluorodeoxyglucose (FDG) positron emission
tomography has become a promising agent for detection of
infected cysts.111,112 FDG is taken up by inflammatory cells
because of their high metabolic rate. Advantages of FDG
positron emission tomography include: rapid imaging (1 h);
high spatial resolution; high target-to-background ratio; low
radiation burden; and high inter-observer agreement. Dis-
advantages are higher cost and limited availability. Its use to
diagnose infections in kidneys may be difficult, particularly
when GFR is normal, because FDG is filtered by the kidneys
(it is not reabsorbed by the tubules) and appears in the
collecting system. By the time positron emission tomography
scans are acquired, the renal parenchyma is usually free of
activity, but prominent activity can be seen in renal calyces.
Dual energy CT is increasingly used to distinguish between
calcium and uric acid stones.113,114
EXTRARENAL MANIFESTATIONS
Polycystic liver disease is the most common extrarenal
manifestation. It is associated with both PKD1 and non-
PKD1 genotypes. PLD also occurs as a genetically distinct
disease in the absence of renal cysts. Similar to ADPKD,
ADPLD is genetically heterogeneous, with two genes
identified (PRKCSH and SEC63) accounting for approxi-
mately one-third of isolated ADPLD cases.
The liver cysts arise by excessive proliferation and
dilatation of biliary ductules and peribiliary glands. Scanning
electron microscopy has shown that the cyst epithelium
displays heterogeneous features, being normal in small cysts
(o1 cm), characterized by rare or shortened cilia in 1–3-cm
cysts, and showing absence of both primary cilia and
microvilli in large cysts (43 cm).115 Estrogen receptors,
insulin-like growth factor 1, insulin-like growth factor 1
receptors (IGF1-R), and growth hormone receptor are
expressed in the epithelium lining the hepatic cysts, and
estrogens and IGF1 stimulate hepatic cyst-derived cell
proliferation.115,116 Growth is also promoted by growth
factors and cytokines secreted into the cyst fluid.117
Comparative analyses of human kidney and liver cyst fluids
have shown disparate cytokine/growth factor profiles. CXCR2
agonists, including interleukin-8, epithelial neutrophil-acti-
vating peptide, growth-related oncogene-a, are potent
proliferative agents that were found at high levels in liver
but not kidney cyst fluids.118
The changes in the expression of certain microRNAs may
contribute to the proliferative phenotype of the cystic
epithelium in PLD.119 A microarray analysis found marked
differences in microRNA expression in cholangiocyte cell
lines derived from PCK rats, as well as in liver tissues from
PCK rats and patients with PLD, compared with controls.
Specifically, a reduced expression of miR15a in the cystic
tissues was associated with upregulation of its target, the cell-
cycle regulator cell division cycle 25A (Cdc25A). Over-
expression of miR15a in cholangiocytes from PCK rats
decreased Cdc25A levels, inhibited cell proliferation, and
reduced cyst growth. Suppression of miR15a in normal rat
cholangiocytes accelerated cell proliferation, increased
Cdc25A expression, and promoted cyst growth.
As shown earlier for PKD, cAMP seems to play a major
role in the progression of PLD. Two main downstream
effectors of cAMP are cAMP-guanine nucleotide exchange
factor/Epac (Epac) and PKA. Although only PKA has been
implicated in the proliferative response to cAMP in PKD,
both effector pathways may be important in PLD.120 Epac1
and Epac2 isoforms and the PKA RIb subunit are over-
expressed in cultured PCK cholangiocytes. Epac-specific
stimulation promotes the proliferation of both, normal and
PCK cholangiocytes, whereas PKA-specific stimulation sup-
presses proliferation in normal cholangiocytes and enhances
it in PCK cholangiocytes. The stimulatory effects of Epac and
PKA activation on the proliferation of PCK cholangiocytes
were both dependent on MEK-ERK1/2 signaling. The
increased proliferation of PCK cholangiocytes in response
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to PKA stimulation, but not to Epac stimulation, was found
to be associated with decreased intracellular calcium.
Restoration of calcium levels blocked the PKA-dependent
proliferation. As described earlier for renal cyst-derived cells,
the effect of intracellular calcium restoration on slowing
PKA-associated proliferation was abolished by preincubation
of PCK cholangiocytes with PI3K or AKT inhibitors.
Hepatic cysts are rare in children. Their frequency
increases with age and may have been underestimated
by ultrasound and CT studies. Their prevalence by MRI in
the CRISP study is 58, 85, and 94% in 15–24, 25–34,
and 35–46 years old participants.121 Hepatic cysts are
more prevalent and hepatic cyst volume is larger in women
than in men.
Typically, PLD is asymptomatic, but symptoms have
become more frequent as the lifespan of ADPKD patients has
lengthened with dialysis and transplantation. Symptoms may
result from mass effect or from complications related to the
cysts. Symptoms typically caused by massive enlargement of
the liver or by mass effect from a single or a limited number
of dominant cysts include dyspnea, early satiety, gastro-
esophageal reflux, and mechanical low back pain. Other
complications caused by mass effect include hepatic venous
outflow obstruction, inferior vena cava compression, portal
vein compression, or bile duct compression presenting as
obstructive jaundice. Symptomatic cyst complications in-
clude cyst hemorrhage, infection, and rarely torsion or
rupture. FDG positron emission tomography scanning is a
promising diagnostic tool for cyst infection.111 Rupture of an
infected liver cyst into the pericardium and bronchobiliary
fistulas are rare recently reported complications.122,123
The seminal vesicles, pancreas, and arachnoid membrane
cysts are present in 40–60% (males), 5, and 8% of patients,
respectively. Epididymal and prostate cysts may also occur
with increased frequency. Sperm abnormalities and defective
motility (asthenozoospermia or o50% of spermatozoa with
forward motility) are common in ADPKD and rarely may be
a cause of male infertility.124 Pancreatic cysts are almost
always asymptomatic, with very rare occurrences of recurrent
pancreatitis and possibly chance associations of intraductal
papillary mucinous tumor or carcinoma. Spinal meningeal
diverticula may occur with increased frequency and rarely
present with intracranial hypotension (orthostatic headache,
diplopia, hearing loss, ataxia) due to cerebrospinal
fluid leak.125
Vascular manifestations include intracranial aneurysms
and dolichoectasias, thoracic aortic and cervicocephalic
artery dissections, and coronary artery aneurysms. They are
caused by alterations in the vasculature directly linked to
mutations in PKD1 or PKD2.126 Intracranial aneurysms are
very prevalent (6% with a negative and 16% with a positive
family history of aneurysms), but most never rupture.
Valvular heart disease (mitral valve prolapse and aortic
insufficiency) occurs with increased frequency. Colonic
diverticulosis and diverticulitis are more common in ESRD
patients with ADPKD than in those with other renal diseases.
There have been reports of extracolonic diverticular dis-
ease.127 A rarely reported association of ADPKD is with
idiopathic hypertrophic pyloric stenosis.128 This may repre-
sent a chance association, but a deficiency in nitric oxide
synthase could be the underlying cause of both conditions.
PC1 is expressed in the motile cilia of airway epithelial cells.
Bronchiectasis are detected by CT three times more
frequently in ADPKD compared with control individuals
(37 vs 13%, Po0.002).129
ADPKD DIAGNOSED IN UTERO OR AT BIRTH
More fetuses are now diagnosed with ADPKD due to the
routine use of fetal ultrasonography. A report from a single
center on 29 consecutive cases detected between the 12th
week of pregnancy and the first day of life between 1981 and
2006 showed that the prognosis is usually favorable, at least
during childhood.130 Clinical features in 26 children (three
pregnancies were terminated because of prenatal signs of
poor prognosis) included oligoamnios in five and neonatal
pneumothorax in three. At the last follow-up (mean
duration: 76 months; range: 0.5–262 months), 19 children
(mean age: 5.5 years) were asymptomatic, 5 (8.5 years) had
hypertension, 2 (9.7 years) proteinuria, and 2 (19 years)
chronic renal insufficiency.
TREATMENT
Current therapy is directed toward limiting the morbidity
and mortality from the complications of the disease and has
been the focus of recent reviews.3,131–133 The discussion here
is limited to information that has become available in the last
3 years.
Although some studies have shown better preservation of
renal function or reduction in proteinuria and left ventricular
hypertrophy with ACEIs or ARBs compared with diuretics or
calcium channel blockers, others have been unable to detect a
superiority of these drugs compared with b-blockers. Most
studies have been limited by inadequate power, short follow-
ups, wide ranges of renal function, and doses with inadequate
pharmacological effects. Equally uncertain is the optimal
blood pressure target. Although ADPKD patients with a
baseline GFR between 13 and 24 ml/min per 1.73 m2 assigned
in the MDRD study to a low blood pressure target
(o92 mm Hg) had faster decline in GFR than those assigned
to a standard blood pressure goal (o107 mm Hg), an
extended follow-up of the patients with a baseline GFR
between 25 and 55 ml/min per 1.73 m2 showed a delayed
onset of kidney failure and a reduced composite outcome of
kidney failure and all-cause mortality in the low blood
pressure group. An ongoing study (HALT-PKD) is designed
to determine whether the combined therapy with an ACEI
and an ARB is superior to an ACEI alone in delaying the
progression of the cystic disease in patients with CKD stage 1
or 2 or in slowing down the decline of renal function in
patients with CKD stage 3. HALT-PKD will also determine
whether a low blood pressure target (o110/75) is superior to
a standard blood pressure target (o130/80) in the group of
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patients with preserved function (NCT00283686; Clinical
Trials.gov).
Several studies have suggested a beneficial effect of statins
on endothelial function, renal blood flow, and levels of
interleukin-6 and C-reactive protein.134 Administration of
lovastatin to cy/þ rats increased renal blood flow and
ameliorated the renal cystic disease, but the beneficial effects
from the administration lovastatin and enalapril on the
severity of the cystic disease were not additive.135
Dietary supplementation with long-chain n-3 polyunsa-
turated fatty acids has been shown to have beneficial anti-
inflammatory effects in cy/þ rats. However, a small
prospective randomized trial of eicosapentaenoic acids
(EPA, 2.4 g daily for 2 years) in ADPKD patients (21 treated
with EPA and 20 controls; mean plasma creatinine concen-
trations, 1.75 and 1.56 mg per 100 ml; mean total kidney
volumes, 1806 and 1563 ml) did not show a beneficial effect
on rates of renal enlargement or functional decline.136
The management of chronic pain in a relatively small
subset of patients for whom it may be disabling is
challenging. When conservative measures fail, surgical
interventions ranging from cyst aspiration and sclerosing
agents to laparoscopic or surgical cyst fenestration can be
considered. A nonrandomized, open label, uncontrolled trial
of videothoracoscopic sympatho-splanchnicectomy is on-
going (NCT00571909). Laparoscopic renal denervation and
nephropexy have provided good results in children with
chronic flank pain and intermittent severe episodes.137
Laparoscopic or retroperitoneoscopic nephrectomy is indi-
cated for symptomatic patients with ESRD. Renal artery
embolization can also be considered in these cases. It has
been reported to produce a decrease in kidney size to 73.8%
at 3 months and to 53.4% of the original size at 1 year.
Side effects include flank pain which resolves within 5 days,
fever which lasts an average of 8.2 days, nausea and
vomiting.138–140
Transplantation is the treatment of choice for ESRD in
ADPKD. Complications after transplant are no greater than
in the general population. Complications directly related to
ADPKD are rare. Whether ADPKD increases the risk for
developing new onset diabetes mellitus after transplantation
is controversial.141,142 When nephrectomy is indicated, hand-
assisted laparoscopic nephrectomy is associated with less
intraoperative blood loss, less postoperative pain, and a faster
recovery compared with open nephrectomy and is increas-
ingly being used.143–145
Most cases of PLD require no treatment. Rarely, sympto-
matic PLD requires interventions to reduce cyst volume and
hepatic size. The choice of procedure (percutaneous cyst
aspiration without or with sclerosis, laparoscopic cyst
fenestration, combined liver resection and cyst fenestration,
and liver transplantation) is dictated by the anatomy and
distribution of the cysts.146 Hepatic artery embolization has
been used mainly in Japan and can be considered for highly
symptomatic patients in whom the other options are not
feasible or too risky.147
Widespread pre-symptomatic screening is not indicated
because it yields mostly small aneurysms with a low risk of
rupture. Indications for screening in patients with good life
expectancy include family history of aneurysm or subar-
achnoid hemorrhage, previous aneurysm rupture, prepara-
tion for major elective surgery, high-risk occupations (for
example, airline pilots), and patient anxiety despite adequate
information. MR angiography does not require intravenous
contrast material. CT angiography is a satisfactory alternative
when there is no contraindication to intravenous contrast.
When an asymptomatic aneurysm is found, a recommenda-
tion on whether to intervene depends on its risk of rupture
(determined by size, site, morphology, and before history of
subarachnoid hemorrhage from another aneurysm), patient
age and general health, and whether the aneurysm is coilable
or clippable.148
NOVEL THERAPIES
A better understanding of the pathophysiology and the
availability of animal models has facilitated the development
of preclinical trials (Figure 2) and identification of promising
candidate drugs for clinical trials (Table 4).
The effect of vasopressin, through V2 receptors, on cAMP
levels in the collecting duct, the major site of cyst
development in ADPKD, and the role of cAMP in
cystogenesis provided the rationale for preclinical trials of
vasopressin V2 receptor (VPV2R) antagonists. One of these
drugs, OPC-31260, reduced the renal levels of cAMP and
markedly inhibited cyst development in models of ARPKD,
ADPKD, and nephronophthisis.110 An antagonist with high
potency and selectivity for the human VPV2R (tolvaptan)
was also effective. Neither had an effect on liver cysts,
consistent with the absence of VPV2R in the liver. High water
intake by itself also exerted a protective effect on the
development of PKD in PCK rats most likely due to
suppression of vasopressin.149 Genetic elimination of AVP
in these rats yielded animals born with normal kidneys that
remained relatively free of cysts unless an exogenous V2R
agonist was administered.150 An antagonist of the endothe-
lin-1 ETB receptor (predominant endothelin receptor sub-
type in the collecting tubules that inhibits AVP action and
promotes diuresis) increased renal cAMP and aggravated the
renal cystic disease in Pkd2WS25/ mice, presumably by
enhancing the action of AVP.151 Phase II clinical trials with
tolvaptan have been completed and a phase III clinical trial is
ongoing (NCT00428948).
Somatostatin acting on SST2 receptors inhibits cAMP
accumulation not only in the kidney but also in the liver.152
Octreotide, a metabolically stable somatostatin analog, halted
the expansion of hepatic cysts from PCK rats in vitro and
in vivo. Similar effects were observed in the kidneys. These
observations are consistent with the inhibition of renal
growth in a pilot study of long-acting octreotide for human
ADPKD and provide support for ongoing clinical trials of
octreotide and lanreotide for PKD and PLD (NCT00309283,
NCT00426153, NCT00565097).
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Correcting the alteration in intracellular calcium home-
ostasis thought to be responsible for the accumulation of
cAMP and the proliferative phenotype of the cystic
epithelium is a logical alternative strategy to inhibit the
development of PKD. The aggravation of PKD in cy/þ rats
by the administration of calcium channel blockers is
consistent with this strategy.153 Triptolide induced cellular
calcium release through a PC2-dependent pathway, increased
p21 expression and arrested growth in Pkd1/ cells, and
reduced cystic burden in Pkd1/ embryonic mice and in
kidney-specific conditional Pkd1 knockout mice.154,155 On
the other hand, amlodipine has been reported to have an
antiproliferative effect in vascular smooth muscle cells by
increasing the expression of p21 (Waf1/Cip1).156 The
administration of a type 2 calcimimetic caused a slight
reduction in interstitial fibrosis, but had no detectable
effect on the levels of renal cAMP, renal expression of
cAMP-dependent genes, and cystogenesis in the PCK rat and
Pkd2/WS25 mouse, possibly due to the absence of calcium-
sensing receptor in the outer medullary and cortical
collecting ducts or the reduction in extracellular calcium.84
The transporters required for chloride-driven fluid secre-
tion into the cysts (NaK2Cl cotransporter, Na-K-ATPase,
CFTR, and KCa3.1) have been targeted to inhibit cyst growth
(Figure 2). CFTR inhibitors slowed cyst growth in an MDCK
cell culture model, in metanephric kidney organ cultures, and
in Pkd1flox/–;Ksp-Cre mice.157,158 These observations are
consistent with reports of families with both ADPKD and
cystic fibrosis in which individuals with both diseases had less
severe cystic disease than those with only ADPKD.159 CFTR
inhibitors that achieve high concentrations in the kidney and
urine may find a place in the treatment of ADPKD, because
their accumulation in the lung is minimal and CFTR
inhibition has to exceed 90% to affect lung function, thus
making the development of cystic fibrosis-like lung disease
unlikely.
A KCa3.1 inhibitor, TRAM-34 (an analog of des-
imidazolyl clotrimazole), inhibited forskolin-stimulated
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Figure 2 | Diagram depicting putative pathways up- or downregulated in polycystic kidney disease and rationale for treatment
with V2 receptor antagonists, somatostatin, triptolide; tyrosine kinase, src, MEK, TNFa, mTOR, or CDK inhibitors; metformin, and
CFTR or KCa3.1 inhibitors (green boxes). Dysregulation of [Ca2þ ]i, increased concentrations of cAMP, mislocalization of ErbB receptors,
and upregulation of EGF, IGF1, VEGF, and TNFa occur in cells/kidneys bearing PKD mutations. Increased accumulation of cAMP in polycystic
kidneys may result from: (i) disruption of the polycystin complex, as PC1 may act as a Gi protein-coupled receptor; (ii) stimulation of Ca2þ
inhibitable AC6 and/or inhibition of Ca2þ -dependent PDE1 by a reduction in [Ca2þ ]i; (iii) increased levels of circulating vasopressin due to
an intrinsic concentrating defect; and/or (iv) upregulation of vasopressin V2 receptors. Increased cAMP levels contribute to cystogenesis by
stimulating chloride and fluid secretion. In addition, cAMP stimulates mitogen-activated protein kinase/extracellularly regulated kinase
(MAPK/ERK) signaling and cell proliferation in an Src- and Ras-dependent manner in cyst-derived cells or in wild-type tubular epithelial cells
treated with Ca2þ channel blockers or in a low Ca2þ medium. Activation of tyrosine kinase receptors by ligands present in cystic fluid also
contributes to the stimulation of MAPK/ERK signaling and cell proliferation. Phosphorylation of tuberin by ERK (or inadequate targeting to
the plasma membrane due to defective interaction with polycystin-1) may lead to the dissociation of tuberin and hamartin and lead to the
activation of Rheb and mTOR. Upregulation of TNFa or downregulation of AMPK signaling may also stimulate mTOR signaling through
inhibition of the tuberin–hamartin complex. Activation of AMPK may also blunt cystogenesis through inhibition of CFTR and ERK.
Upregulation of Wnt signaling stimulates mTOR and b-catenin signaling. ERK and mTOR activation promotes G1/S transition and cell
proliferation through regulation of cyclin D1, phosphorylation of retinoblastoma protein (RB) by CDK4/6-cyclin D and CDK2-cyclin E, and the
release of the E2F transcription factor. AC-VI, adenylate cyclase 6; AMPK, AMP kinase; CDK, cyclin-dependent kinase; ER, endoplasmic
reticulum; MAPK, mitogen-activated protein kinase; mTOR, mammalian target of rapamycin; PC1, polycystin-1; PC2, polycystin-2; PDE,
phosphodiesterase; PKA, protein kinase A; R, somatostatin sst2 receptor; TSC, tuberous sclerosis proteins tuberin (TSC2) and hamartin
(TSC1); V2R, vasopressin V2 receptor; V2RA, vasopressin V2 receptor antagonists.
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transepithelial chloride secretion in filter-grown polarized
monolayers of MDCK, NHK, and ADPKD cells, as well as
MDCK and ADPKD cell cyst formation and enlargement in
collagen gels.73,74 Although the efficacy of KCa3.1 inhibitors
in ADPKD still needs to be shown in animal models of the
disease, it is encouraging that senicapoc (ICA-17043),
another KCa3.1 inhibitor, has been used successfully in a
phase 2 trial and has shown little or no toxicity in a phase 3
trial for sickle-cell disease.160
Targeting the NaK2Cl cotransporter or Na-K-ATPase to
treat ADPKD seems less feasible because of likely side effects
and less predictable effects on cystogenesis. Inhibition of the
NaK2Cl cotransporter could potentially be detrimental as
hypokalemia has been associated with chronic stimulation of
COX-2 and PGE2 production and may favor cyst develop-
ment. Addition of relatively high concentrations of ouabain
to basolateral but not apical membranes of ADPKD cell
monolayers and intact cysts dissected from ADPKD kidneys
inhibited fluid secretion. However, nanomolar concentra-
tions of ouabain, within the range of levels found in blood
under normal conditions increase ERK phosphorylation and
MEK-ERK-dependent proliferation of ADPKD cells, without
a significant effect on normal human kidney cells.161
Patients with the contiguous PKD1-TSC2 gene syndrome
show a more severe form of PKD than those with ADPKD
alone. This observation suggests a convergence of signaling
Table 4 | Currently active clinical trials for ADPKD
Intervention Study design Eligibilitya
Enrollment target
and primary outcome
measure
Start–finish
dates (status) Sponsor
HALT-PKD Study A
phase 3
NCT00283686
Lisinopril/telmisartan vs
lisinopril/placebo and
low vs standard BP
target
Multicenter,
randomized, double-
blind, placebo-
controlled, 2 2
factorial assignment
15–49 years old, GFR
460, BPX130/80, or
treatment for HT
548, Kidney volume
change (MRI)
2006–2013
(recruiting)
NIDDK
HALT-PKD Study B
phase 3
NCT00283686
Lisinopril/telmisartan vs
lisinopril/placebo
Multicenter,
randomized, double-
blind, placebo-
controlled
18–64 years old, GFR
25–60, BP X130/80,
or treatment for HT
470, Time to the 50%
reduction in eGFR, ESRD,
or death
2006–2013
(recruitment
closed)
NIDDK
Effect of Statin on
disease progression
phase 3
NCT00456365
Pravastatin Randomized, double-
blind, placebo-
controlled
8–21 years old,
Normal GFR
100, Kidney volume,
LVMI, urine albumin,
endothelial-dependent
vasodilation
2006–2011
(recruiting)
University of
Colorado
TEMPO 2/4 Trial
phase 2
NCT00413777
V2 receptor antagonist
(tolvaptan)
Multicenter, open-
label, dose
comparison
418 years old
Participation in prior
dose-finding studies
48, Long-term safety
(kidney volume sec.
outcome)
2005–2008
(recruitment
closed)
Otsuka
Pharm.
TEMPO 3/4 Trial
phase 3
NCT00428948
V2 receptor antagonist
(tolvaptan)
Multicenter, double-
blind, placebo-
controlled
18–40 years old
GFRX60, TKV
X750 ml
1500, Kidney volume
change (MRI)
2007–2011
(recruiting)
Otsuka
Pharm.
Octreotide in ADPKD
phase 3
NCT00309283
Long-acting
somatostatin
(octreotide)
Randomized, single-
blind, placebo-
controlled
18–75 years old, GFR
440
66, Kidney volume
change (MRI)
2006–2010
(recruiting)
Mario Negri
Institute
Octreotide in severe
PLD phase 2–3
NCT00426153
Long-acting
somatostatin
(octreotide)
Randomized, double-
blind, placebo-
controlled, crossover
418 years old,
LV44000 ml or
highly symptomatic
PLD
42, Liver volume change
(MRI) (kidney volume
sec. outcome)
2007–2010
(recruitment
closed)
Mayo Clinic,
Novartis
Lanreotide in PLD
phase 2–3
NCT00565097
Long-acting
somatostatin (lanreotide)
Randomized, double-
blind, placebo-
controlled
418 years old, 420
liver cysts
38, Liver volume change
(CT)
2007-
(recruitment
closed)
Radboud
University,
Ipsen
SUISSE study phase 3
NCT00346918
mTOR inhibitor
(sirolimus)
Multicenter,
randomized, single-
blind, placebo-
controlled
18–40 years old, GFR
X70
100, Kidney volume
change (MRI)
2006–2010
(recruitment
closed)
University
of Zurich
SIRENA STUDY phase
2 NCT00491517
mTOR inhibitor
(sirolimus)
Randomized, open-
label, crossover
18–80 years old, GFR
X70
16, Kidney volume
change (CT)
2007–2009
(recruiting)
Mario Negri
Institute
Sirolimus in ADPKD
phase 1–2
NCT00286156
mTOR inhibitor
(sirolimus)
Randomized, open-
label, dose
comparison
18–75 years old 45, Lothalamate GFR
change
(recruiting) Cleveland
Clinic
Everolimus in ADPKD
phase 3
NCT00414440
mTOR inhibitor
(everolimus)
Multicenter,
randomized,
placebo-
controlled, double-
blind
18–65 years old,
GFRX60
400, Kidney volume
change (MRI)
2006–2009
(recruiting)
Novartis
ADPKD Pain Study
phase 2
NCT00571909
Videothoracoscopic
sympatho-
splanchnicectomy
Nonrandomized,
open-label,
uncontrolled
418 years old,
debilitating kidney
pain
20, Pain control and
quality of life
2007–2010
(recruiting)
Mayo Clinic,
PKDF
BP, blood pressure; CT, computed tomography; ESRD, end-stage renal disease; GFR, glomerular filtration rate; MRI, magnetic resonance imaging; PLD, polycystic liver disease.
aGFR, estimated or measured, in ml/min or ml/min per 1.73 m2; BP in mm Hg.
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pathways downstream from PC1 and the TSC2 protein
tuberin (Figure 2). Activation of mTOR in polycystic kidneys
and an interaction between PC1 and tuberin have been
reported.162 Furthermore, studies in three rodent models of
PKD have shown that the mTOR inhibitors sirolimus and/or
everolimus significantly retard cyst expansion and protects
renal function.69,162–165 Small retrospective studies of ADPKD
patients after transplantation have shown a significant
reduction in the volume of the polycystic kidneys or
polycystic liver in patients treated with sirolimus compared
with patients treated with calcineurin inhibitors.162,166
Prospective, randomized clinical trials of rapamycin and
everolimus are in progress (NCT00346918, NCT00491517,
NCT00286156, NCT00414440).
It has been suggested that AMP-activated protein kinase
activation might have a beneficial effect on the development
of PKD as it directly phosphorylates and inhibits CFTR
and inhibits mTOR through phosphorylation of tuberin
(Figure 2). Consistent with this, metformin has been shown
to reduce the growth of MDCK cysts and the cystic index of
conditional kidney-specific Pkd1 knockout mouse.167
One of the effects of mTOR inhibition is to inhibit the
production of and the cellular response to vascular
endothelial growth factor. Vascular endothelial growth factor
is present in ADPKD liver and kidney cyst fluids, and VEGF
receptors 1 and 2 (VEGFR1 and VEGFR2) are present in
cystic tissues. The results of VEGF inhibition in PKD have
been mixed. Administration of the VEGFR inhibitor SU-5416
had a significant protective effect on the development of
cystic disease in the liver, but not in the kidney, in a small
number of Pkd2WS25/ mice.168 On the other hand, treatment
of developing CD-1 mice with antibodies against VEGFR2
results in the development of renal cysts, suggesting that
inhibition of VEGF signaling could promote renal cyst
growth.169
Tumor necrosis factor-a, TNFR-I, and TNF-a-converting
enzyme are overexpressed in cystic tissues. The administra-
tion of TNF promotes cyst formation in Pkd2þ / mice,
whereas etanercept had an inhibitory effect.18 An inhibitor of
TNF-a-converting enzyme was shown to ameliorate the
polycystic disease in the bpk mouse, a recessive model of
PKD. The aggravation of PKD by TNFa may be due to its
enhancement of the expression of FIP2, a protein that
physically interacts with polycystin 2 and prevents its
transport to the plasma membrane and primay cilium.
Alternatively, TNFa also activates IKKb (inhibitor of kB
kinase-b), which physically interacts and phosphorylates
hamartin, suppressing TSC1-TSC2 function and activating
mTOR.119 (Figure 2).
Polycystic kidney disease has been described as ‘neoplasm
in disguise’, Many drugs developed to suppress cell prolifera-
tion and treat neoplastic diseases have been shown in animal
models to be effective and of potential value for the treatment
of ADPKD. These include Erb-B1 (EGF receptor) and Erb-B2
tyrosine kinase, Src kinase, MEK, and cdk inhibitors.170–172
Roscovitine, a cyclin-dependent kinase inhibitor, inhibited
cystogenesis and improved renal function in two murine
models of PKD, acting through blockade of the cell cycle,
transcriptional regulation, and inhibition of apoptosis.173
Similar to PC1, roscovitine has been shown to increase the
levels of p21, which is downregulated in PKD.67
Increased apoptosis accompanies increased cell prolifera-
tion in PKD, but it is unclear whether it is a neutral or
beneficial consequence of excessive proliferation or an
important contributor to cyst formation and renal injury.
A caspase inhibitor (IDN-8050) reduced epithelial cell
apoptosis and proliferation, and inhibited the development
of the cystic disease and renal insufficiency in Han:SPRD
rats.69 Double mutants with PKD (cpk mice) and a knockout
of caspase 3 had less severe cystic disease and lived longer
than cpk mice with intact caspase 3.174
A number of studies have focused on the role of
arachidonic acid metabolites and their inhibitors on the
progression of PKD. Prostaglandin E2 (PGE2) accumulates in
cyst fluids and enhances cAMP production and growth of
MDCK cysts in collagen gels.175 PGE2 may act on four
different G-protein-coupled receptors named E-prostanoid
(EP) receptors 1–4. EP2 and EP4 are coupled to G
stimulatory proteins and stimulate cAMP formation. EP3 is
coupled to G inhibitory protein, inhibits cAMP formation,
induces Rho activation and actin polymerization, and
antagonizes vasopressin action. EP1 activation induces
inositol 3-phosphate formation and calcium release. Recently,
the effects of PGE2 on cAMP formation and cystogenesis, in
a three-dimensional cell-culture system of human epithelial
cells from normal and ADPKD kidneys, have been shown to
be mediated by EP2 receptor activation, thus suggesting a
possible role for EP2 receptor antagonists in the treatment of
ADPKD.175
Phospholipase A, COX-1 and COX-2 activities and the
production of prostacyclin, thromboxane A2, and PGE2 are
higher in cystic than wild-type kidneys. Endogenous and
steady state in vitro levels of prostanoids were 2–10 times
higher in diseased compared with normal kidneys. The
administration of the COX-2 inhibitor NS-398 reduced cystic
expansion by 18%, interstitial fibrosis by 67%, macrophage
infiltration by 33%, cell proliferation by 38%, and presence of
oxidized low-density lipoprotein by 59% compared with
controls, but had no protective effect on renal function.176
The production of 20-hydroxyeicosatetraenoic acid (20-
HETE), an endogenous cytochrome P450 metabolite of
arachidonic acid with mitogenic properties, is markedly
increased in microsomes from bpk compared with wild-type
mice.177 Daily administration of HET-0016, an inhibitor of
20-HETE synthesis, reduced kidney size by half and doubled
survival. Transfection of principal cells isolated from wild-
type mice with Cyp4a12 induced a four- to fivefold increase
in cell proliferation, which was completely abolished when
20-HETE synthesis was inhibited. These observations suggest
that 20-HETE contributes to the proliferation of epithelial
cells in the formation of renal cysts and provide another
potential target for intervention.
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STRATEGIES FOR CLINICAL TRIALS
In planning clinical trials for ADPKD, the utilization of
renal function as the primary outcome becomes an issue.
Decades of normal renal function, despite progressive
enlargement and cystic transformation of the kidneys,
characterize the natural history of ADPKD. By the time
GFR starts declining, the kidneys are markedly enlarged,
distorted, and unlikely to benefit from treatment. On the
other hand, early interventional trials would require
unrealistic periods of follow-up if renal function was to be
used as the primary outcome. The results of CRISP178 have
shown that the rate of renal growth is exponential and a good
predictor of functional decline. Extrapolation of total kidney
volume in individual CRISP subjects back to an age of 18
years is consistent with the volumes observed by direct
measurement in a separate cohort of patients. The good fit
between these extrapolated and measured values indicates
that the total kidney volume growth rate is a defining trait for
individual patients.178 The results of the CRISP study have
been confirmed by a recent European study that has shown
that increases in kidney volume can be reliably measured over
a 6 month period in early ADPKD, using unenhanced MRI
sequences.99 These observations provide a strong rationale
for the utilization of kidney volume as a surrogate marker of
disease progression in clinical trials for ADPKD.
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